Lilly's GLP-1 Pill Wins FDA Nod; Medicare Rate Boost Lifts UNH

Weight-loss drug approval and MA reimbursement increase drive healthcare optimism

Healthcare Market Overview

Healthcare stocks advanced Wednesday afternoon, with multiple Big Pharma names posting gains. $BMY rose 2.65%, $AMGN climbed 2.89%, and $ISRG added 2.06%, while $GILD gained 1.97% and $JNJ increased 1.21%. $UNH has rebounded following CMS announcing a 2.48% Medicare Advantage reimbursement increase for 2027, reversing earlier market pessimism about the managed care segment.

Big Pharma & Biotech

$LLY secured FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 pill for chronic weight management and obesity, marking an important victory in the intensifying diabetes and obesity market. $AMGN has gained 25% since last April, with MariTide potentially becoming a once-quarterly injection as the company shifts focus away from developing an oral pill. $MRK's stock reached $123.18 with a 1-year total shareholder return of 55.85%, while Cantor Fitzgerald raised $BMY's price target to $54 from $45 but flagged weak Q1 catalysts ahead.

MedTech & Devices

$ISRG closed at $462.28, marking a 2.06% gain from the previous day, though the surgical robotics leader underperformed the broader market. $ABT rose 1.7% to $103.56 in recent trading, also lagging behind overall market performance.

FDA & Regulation

The FDA approved $LLY's Foundayo (orforglipron) as a once-daily oral GLP-1 pill for chronic weight management, addressing surging demand in the obesity treatment market. The approval comes as the competitive landscape in GLP-1 therapies intensifies, with multiple pharmaceutical companies advancing both injectable and oral formulations.

Looking Ahead

$MRNA is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results, according to Bank of America analysts. The 2025-2026 vaccine season is winding down as the company focuses on geographic expansion. $LLY also announced achieving a second development milestone under its multi-target collaboration with Nxera Pharma targeting diabetes and metabolic diseases, with payment amounts undisclosed.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy